Agreement - June 16, 2017
Cantargia enters collaboration agreement
Swedish Cantargia and Panorama Research Inc, a California based specialist antibody developer, have entered into a collaboration agreement to jointly accelerate Cantargia’s second program directed towards autoimmune and inflammatory diseases. Cantargia’s antibodies, against the molecular target IL1RAP, will be affinity matured and humanized using Panorama’s technology. In addition, Panorama will generate cell lines optimized for […]
Clinical Trials - May 15, 2017
Cantargia initiates clinical trial
Cantargia has submitted the first application to start a phase I/IIa clinical trial with the antibody CAN04 in patients, primarily with non-small cell lung cancer or pancreatic cancer. The trial is planned to be performed at several centres in the BeNeLux and Scandinavia. The goal is to start recruitment as quickly as possible after regulatory […]
Biotech Business - April 10, 2017
Cantargia receives Intention to Grant Notice in Europe
Cantargia announces that the company has received an Intention to Grant notice from the European Patent Office for its patent application for the CAN04 product candidate. The patent application, with application number 15714603.6, for which the EPO has issued an Intention to Grant notice, refers to the company’s CAN04 product candidate. The patent protects Cantargia’s […]
Financing - January 24, 2014
Cantargia receives capital injection
Cantargia, a private biopharmaceutical company developing therapeutics for the treatment of leukemia has announced the conclusion of the first step in their financial plan and reinforces the board. Sven Andréasson has been appointed as chairman of the board. Sven Andréasson has extensive experience in both pharmaceutical and biotech companies. He was CEO of Active Biotech […]
